A multicenter and prospective study of multidisciplinary treatment including surgical lung resection for cN0 non-small cell lung cancer patients with synchronous single organ oligometastasis (ILO 1503)

A multicenter and prospective study of multidisciplinary treatment including surgical lung resection for cN0 non-small cell lung cancer patients with synchronous single organ oligometastasis (ILO 1503) - Surgical lung resection for non small cell lung cancer with synchronous single organ oligometastasis. (ILO1503)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021637

Enrollment

Registered

2016-03-29

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Do all the treatments of the following 1-3 in any order. 1. Complete resection of primary lung cancer. 2. Any local treatment for synchronous metastasis. 3. Systemic chemotherapy (platinum doublet,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Preoperative diagnosis as primary non-small cell lung cancer Clinical stage, T1a-T4, N0M0 Lobectomy, bi-lobectomy or pneumonectomy Synchronous oligometastasis of single organ with one lesion (for brain metastases, 5 or less lesions treatable with gamma-knife) Aged 20-80 years old ECOG PS0,1 Having operability Written informed consent

Exclusion criteria

Exclusion criteria: Active other malingant tumor HBV, HCV, HIV Fever up over 38 degree Having steroid therapy Bilateral adrenal metastases, bilateral renal metastases, bone metastases M1a (contralateral lung metastases, malignant pleural effusion, malignant pericardial effusion, pleural dissemination) Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
2-year overall survival rate	—

Secondary

Measure	Time frame
2-year disease-free survival rate, 5-year overall survival rate, 5-year disease-free survival rate, adverse event, site of relapse	—

Countries

Japan

Contacts

Public ContactTetsukan Woo

Saiseikai Yokohama City South Hospital Thoracic surgery

tetsu.n.u@cotton.ocn.ne.jp045-832-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026